Proteomics International Laboratories Limited advised that it is in the closing stages of finalising the detailed terms of its Exclusive Licence Agreement with Sonic Healthcare USA for use of the Company's PromarkerD predictive test for diabetic kidney disease in the United States. The parties signed a binding and exclusive letter of intent in August to enter into an Exclusive Licence Agreement for the PromarkerD predictive test. The Company will update the market once the Exclusive Licence Agreement has been signed.
Proteomics International Laboratories Limited
Equities
PIQ
AU000000PIQ0
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.095 AUD | +0.46% | +0.46% | +22.35% |
Mar. 25 | Proteomics International Signs Agreement with University of Oxford for Endometriosis Study | MT |
Mar. 19 | Proteomics Says PromarkerD's US Launch Delayed | MT |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+22.35% | 93.47M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- PIQ Stock
- News Proteomics International Laboratories Limited
- Proteomics International Laboratories Limited Provides Update on Exclusive Licence Agreement with Sonic Healthcare USA, Inc